Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
61
BMY Quote, Financials, Valuation and Earnings
Last price:
$54.45
Seasonality move
:
12.83%
Day range:
$52.06 - $53.36
52-week range:
$42.52 - $63.33
Dividend yield:
4.69%
P/E ratio:
17.92x
P/S ratio:
2.25x
P/B ratio:
5.82x
Volume:
14.1M
Avg. volume:
15.6M
1-year change:
-6.2%
Market cap:
$108B
Revenue:
$48.3B
EPS (TTM):
$2.96
Analysts' Opinion
-
Consensus RatingBristol Myers Squibb Co. has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 18 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $55.09, Bristol Myers Squibb Co. has an estimated upside of 3.82% from its current price of $53.06.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $37.00 representing 100% downside risk from its current price of $53.06.
Fair Value
-
According to the consensus of 23 analysts, Bristol Myers Squibb Co. has 3.82% upside to fair value with a price target of $55.09 per share.
BMY vs. S&P 500
-
Over the past 5 trading days, Bristol Myers Squibb Co. has underperformed the S&P 500 by -2.55% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bristol Myers Squibb Co. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bristol Myers Squibb Co. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Bristol Myers Squibb Co. reported revenues of $12.2B.
Earnings Growth
-
Bristol Myers Squibb Co. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Bristol Myers Squibb Co. reported earnings per share of $1.08.
Enterprise value:
142.6B
EV / Invested capital:
--
Price / LTM sales:
2.25x
EV / EBIT:
10.18x
EV / Revenue:
2.97x
PEG ratio (5yr expected):
--
EV / Free cash flow:
9.32x
Price / Operating cash flow:
7.07x
Enterprise value / EBITDA:
7.52x
Gross Profit (TTM):
$30.9B
Return On Assets:
6.43%
Net Income Margin (TTM):
12.59%
Return On Equity:
34.7%
Return On Invested Capital:
8.82%
Operating Margin:
31.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $44.9B | $47.4B | $48B | $11.9B | $12.2B | |
| Gross Profit | $26.2B | $26.5B | $30.9B | $6.6B | $8.1B | |
| Operating Income | $9B | $8.4B | $14B | $2.3B | $3.8B | |
| EBITDA | $18.9B | $18.5B | $19B | $4.9B | $4.9B | |
| Diluted EPS | $3.94 | -$3.60 | $2.96 | $0.60 | $1.08 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $31.4B | $26.8B | $27.6B | $28.1B | $35.6B | |
| Total Assets | $110.9B | $98.2B | $91.3B | $93.7B | $96.9B | |
| Current Liabilities | $21.5B | $18.9B | $23.5B | $22.6B | $28.1B | |
| Total Liabilities | $73.6B | $65.5B | $62.2B | $76.5B | $78.3B | |
| Total Equity | $37.3B | $32.7B | $29.1B | $17.2B | $18.6B | |
| Total Debt | $45.4B | $39.7B | $38.5B | $51B | $50.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $12.9B | $15B | $16.6B | $5.6B | $6.3B | |
| Cash From Investing | $264M | -$22.5B | -$2.9B | -$219M | -$1.7B | |
| Cash From Financing | -$13.6B | $7.7B | -$6B | -$3.9B | -$1.5B | |
| Free Cash Flow | $11.7B | $13.8B | $15.3B | $5.3B | $6B | |
BMY
Sector
Market Cap
$108B
$28.1M
Price % of 52-Week High
83.78%
50.9%
Dividend Yield
4.69%
0%
Shareholder Yield
6.1%
-1.55%
1-Year Price Total Return
-6.21%
-19.36%
Beta (5-Year)
0.288
0.498
Dividend yield:
4.69%
Annualized payout:
$2.40
Payout ratio:
57.44%
Growth streak:
3 years
Technicals
8-day SMA
Sell
Level
$54.05
200-day SMA
Buy
Level
$48.49
Bollinger Bands (100)
Buy
Level
44.37 - 51.05
Chaikin Money Flow
Buy
Level
2.1B
20-day SMA
Sell
Level
$53.30
Relative Strength Index (RSI14)
Buy
Level
55.85
ADX Line
Buy
Level
33.54
Williams %R
Neutral
Level
-66.443
50-day SMA
Buy
Level
$49.47
MACD (12, 26)
Buy
Level
1.25
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
1.3B
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.0725)
Sell
CA Score
(Annual)
Level (-0.9763)
Buy
Beneish M-Score
(Annual)
Level (-3.764)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.0586)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Stock Forecast FAQ
In the current month, BMY has received 4 Buy ratings 18 Hold ratings, and 1 Sell ratings. The BMY average analyst price target in the past 3 months is $55.09.
-
Where Will Bristol Myers Squibb Co. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bristol Myers Squibb Co. share price will rise to $55.09 per share over the next 12 months.
-
What Do Analysts Say About Bristol Myers Squibb Co.?
Analysts are divided on their view about Bristol Myers Squibb Co. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bristol Myers Squibb Co. is a Sell and believe this share price will drop from its current level to $37.00.
-
What Is Bristol Myers Squibb Co.'s Price Target?
The price target for Bristol Myers Squibb Co. over the next 1-year time period is forecast to be $55.09 according to 23 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 18 analysts rate the stock a Hold.
-
Is BMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bristol Myers Squibb Co. is a Hold. 18 of 23 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BMY?
You can purchase shares of Bristol Myers Squibb Co. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bristol Myers Squibb Co. shares.
-
What Is The Bristol Myers Squibb Co. Share Price Today?
Bristol Myers Squibb Co. was last trading at $54.45 per share. This represents the most recent stock quote for Bristol Myers Squibb Co.. Yesterday, Bristol Myers Squibb Co. closed at $53.06 per share.
-
How To Buy Bristol Myers Squibb Co. Stock Online?
In order to purchase Bristol Myers Squibb Co. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BMY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BMY
Sector
P/E ratio
17.92x
24.09x
PEG ratio
--
-0.01x
P/B ratio
5.82x
1.83x
Price / LTM sales
2.25x
1.59x
Growth Metrics
BMY
Sector
Revenue growth
2.78%
4.68%
Earnings growth
81.02%
10.88%
Revenue (5-year growth)
13.06%
6.45%
Earnings forecast
$1.68
-$0.18
Profitability
BMY
Sector
Profitability FY 2024
$27.4B
$3.6M
Return on invested capital
8.82%
-31.87%
Return on assets
6.43%
-28.18%
Return on equity
34.7%
-37.89%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
5
Estimated Next Earnings Date
Jan
29
Balance Sheet
BMY
Sector
Total cash
$16.5B
$26.2M
Short term investments
$513M
$25.7M
Total assets
$92.6B
$76.7M
Long term debt
$50.6B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
